Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Double blind microarray-based polysaccharide profiling enables parallel identification of uncharacterized polysaccharides and carbohydrate-binding proteins with unknown specificities.

Salmeán AA, Guillouzo A, Duffieux D, Jam M, Matard-Mann M, Larocque R, Pedersen HL, Michel G, Czjzek M, Willats WGT, Hervé C.

Sci Rep. 2018 Feb 6;8(1):2500. doi: 10.1038/s41598-018-20605-9.

2.

Endoplasmic reticulum stress precedes oxidative stress in antibiotic-induced cholestasis and cytotoxicity in human hepatocytes.

Burban A, Sharanek A, Guguen-Guillouzo C, Guillouzo A.

Free Radic Biol Med. 2018 Feb 1;115:166-178. doi: 10.1016/j.freeradbiomed.2017.11.017. Epub 2017 Dec 2.

PMID:
29191461
3.

A Dynamic Mathematical Model of Bile Acid Clearance in HepaRG Cells.

Kaschek D, Sharanek A, Guillouzo A, Timmer J, Weaver RJ.

Toxicol Sci. 2018 Jan 1;161(1):48-57. doi: 10.1093/toxsci/kfx199.

4.

Progressive and Preferential Cellular Accumulation of Hydrophobic Bile Acids Induced by Cholestatic Drugs Is Associated with Inhibition of Their Amidation and Sulfation.

Sharanek A, Burban A, Humbert L, Guguen-Guillouzo C, Rainteau D, Guillouzo A.

Drug Metab Dispos. 2017 Dec;45(12):1292-1303. doi: 10.1124/dmd.117.077420. Epub 2017 Sep 19.

5.

Development of novel monoclonal antibodies against starch and ulvan - implications for antibody production against polysaccharides with limited immunogenicity.

Rydahl MG, Krac Un SK, Fangel JU, Michel G, Guillouzo A, Génicot S, Mravec J, Harholt J, Wilkens C, Motawia MS, Svensson B, Tranquet O, Ralet MC, Jørgensen B, Domozych DS, Willats WGT.

Sci Rep. 2017 Aug 24;7(1):9326. doi: 10.1038/s41598-017-04307-2.

6.

Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways.

Burban A, Sharanek A, Hüe R, Gay M, Routier S, Guillouzo A, Guguen-Guillouzo C.

Sci Rep. 2017 May 12;7(1):1815. doi: 10.1038/s41598-017-01171-y.

7.

From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells.

Burbank MG, Sharanek A, Burban A, Mialanne H, Aerts H, Guguen-Guillouzo C, Weaver RJ, Guillouzo A.

Toxicol Sci. 2017 Jun 1;157(2):451-464. doi: 10.1093/toxsci/kfx062.

8.

Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.

Burbank MG, Burban A, Sharanek A, Weaver RJ, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2016 Nov;44(11):1780-1793. Epub 2016 Aug 18.

9.

Differential sensitivity of metabolically competent and non-competent HepaRG cells to apoptosis induced by diclofenac combined or not with TNF-α.

Al-Attrache H, Sharanek A, Burban A, Burbank M, Gicquel T, Abdel-Razzak Z, Guguen-Guillouzo C, Morel I, Guillouzo A.

Toxicol Lett. 2016 Sep 6;258:71-86. doi: 10.1016/j.toxlet.2016.06.008. Epub 2016 Jun 14.

10.

Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Sharanek A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, Guguen-Guillouzo C.

Sci Rep. 2016 May 12;6:24709. doi: 10.1038/srep24709.

11.

Cellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes.

Sharanek A, Burban A, Humbert L, Bachour-El Azzi P, Felix-Gomes N, Rainteau D, Guillouzo A.

Toxicol Sci. 2015 Oct;147(2):573-87. doi: 10.1093/toxsci/kfv155. Epub 2015 Jul 20.

PMID:
26198044
12.

Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.

Bellwon P, Truisi GL, Bois FY, Wilmes A, Schmidt T, Savary CC, Parmentier C, Hewitt PG, Schmal O, Josse R, Richert L, Guillouzo A, Mueller SO, Jennings P, Testai E, Dekant W.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):62-78. doi: 10.1016/j.tiv.2015.07.016. Epub 2015 Jul 17.

PMID:
26193170
13.

Drug biokinetic and toxicity assessments in rat and human primary hepatocytes and HepaRG cells within the EU-funded Predict-IV project.

Mueller SO, Guillouzo A, Hewitt PG, Richert L.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):19-26. doi: 10.1016/j.tiv.2015.04.014. Epub 2015 May 4. Review.

PMID:
25952325
14.

Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.

Bachour-El Azzi P, Sharanek A, Burban A, Li R, Guével RL, Abdel-Razzak Z, Stieger B, Guguen-Guillouzo C, Guillouzo A.

Toxicol Sci. 2015 May;145(1):157-68. doi: 10.1093/toxsci/kfv041. Epub 2015 Feb 17.

15.

Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems.

Truisi GL, Consiglio ED, Parmentier C, Savary CC, Pomponio G, Bois F, Lauer B, Jossé R, Hewitt PG, Mueller SO, Richert L, Guillouzo A, Testai E.

Toxicol Lett. 2015 Mar 4;233(2):172-86. doi: 10.1016/j.toxlet.2015.01.006. Epub 2015 Jan 8.

16.

Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.

Savary CC, Jiang X, Aubry M, Jossé R, Kopp-Schneider A, Hewitt P, Guillouzo A.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35. doi: 10.1016/j.tiv.2014.12.019. Epub 2015 Jan 5.

17.

In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments.

Pomponio G, Savary CC, Parmentier C, Bois F, Guillouzo A, Romanelli L, Richert L, Di Consiglio E, Testai E.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):36-51. doi: 10.1016/j.tiv.2014.12.012. Epub 2014 Dec 26.

PMID:
25546373
18.

Biokinetics of chlorpromazine in primary rat and human hepatocytes and human HepaRG cells after repeated exposure.

Broeders JJ, Parmentier C, Truisi GL, Jossé R, Alexandre E, Savary CC, Hewitt PG, Mueller SO, Guillouzo A, Richert L, van Eijkeren JC, Hermens JL, Blaauboer BJ.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):52-61. doi: 10.1016/j.tiv.2014.08.012. Epub 2014 Nov 4.

PMID:
25458484
19.

Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells.

Bachour-El Azzi P, Sharanek A, Abdel-Razzak Z, Antherieu S, Al-Attrache H, Savary CC, Lepage S, Morel I, Labbe G, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2014 Sep;42(9):1556-66. doi: 10.1124/dmd.114.058123. Epub 2014 Jul 7.

20.

Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells.

Sharanek A, Azzi PB, Al-Attrache H, Savary CC, Humbert L, Rainteau D, Guguen-Guillouzo C, Guillouzo A.

Toxicol Sci. 2014 Sep;141(1):244-53. doi: 10.1093/toxsci/kfu122. Epub 2014 Jun 27.

21.

Interactions of endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells.

Savary CC, Jossé R, Bruyère A, Guillet F, Robin MA, Guillouzo A.

Drug Metab Dispos. 2014 Aug;42(8):1235-40. doi: 10.1124/dmd.114.057786. Epub 2014 May 15.

22.

PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.

Rogue A, Anthérieu S, Vluggens A, Umbdenstock T, Claude N, de la Moureyre-Spire C, Weaver RJ, Guillouzo A.

Toxicol Appl Pharmacol. 2014 Apr 1;276(1):73-81. doi: 10.1016/j.taap.2014.02.001. Epub 2014 Feb 15.

23.

Impact of isomalathion on malathion cytotoxicity and genotoxicity in human HepaRG cells.

Josse R, Sharanek A, Savary CC, Guillouzo A.

Chem Biol Interact. 2014 Feb 25;209:68-76. doi: 10.1016/j.cbi.2013.12.002. Epub 2013 Dec 12.

24.

Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells.

Anthérieu S, Bachour-El Azzi P, Dumont J, Abdel-Razzak Z, Guguen-Guillouzo C, Fromenty B, Robin MA, Guillouzo A.

Hepatology. 2013 Apr;57(4):1518-29. doi: 10.1002/hep.26160. Epub 2013 Mar 4.

PMID:
23175273
25.

Optimization of the HepaRG cell model for drug metabolism and toxicity studies.

Anthérieu S, Chesné C, Li R, Guguen-Guillouzo C, Guillouzo A.

Toxicol In Vitro. 2012 Dec;26(8):1278-85. doi: 10.1016/j.tiv.2012.05.008. Epub 2012 May 27. Review.

PMID:
22643240
26.

Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds.

Josse R, Dumont J, Fautrel A, Robin MA, Guillouzo A.

Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87. doi: 10.1016/j.taap.2011.10.019. Epub 2011 Nov 4.

PMID:
22100608
27.

An adaptation of the human HepaRG cells to the in vitro micronucleus assay.

Jossé R, Rogue A, Lorge E, Guillouzo A.

Mutagenesis. 2012 May;27(3):295-304. doi: 10.1093/mutage/ger076. Epub 2011 Nov 3.

PMID:
22058015
28.

Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells.

Rogue A, Lambert C, Spire C, Claude N, Guillouzo A.

Drug Metab Dispos. 2012 Jan;40(1):151-8. doi: 10.1124/dmd.111.042028. Epub 2011 Oct 12.

29.

Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes.

Rogue A, Lambert C, Jossé R, Antherieu S, Spire C, Claude N, Guillouzo A.

PLoS One. 2011 Apr 18;6(4):e18816. doi: 10.1371/journal.pone.0018816.

30.

Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.

Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C.

Toxicol Appl Pharmacol. 2011 Jul 1;254(1):18-31. doi: 10.1016/j.taap.2011.04.005. Epub 2011 Apr 14.

PMID:
21515302
31.

Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.

Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA.

Hepatology. 2011 Jun;53(6):1895-905. doi: 10.1002/hep.24290. Epub 2011 May 2.

PMID:
21391224
32.

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.

Rogue A, Spire C, Brun M, Claude N, Guillouzo A.

PPAR Res. 2010;2010:325183. doi: 10.1155/2010/325183. Epub 2010 Oct 19.

33.

Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines.

Dumont J, Jossé R, Lambert C, Anthérieu S, Laurent V, Loyer P, Robin MA, Guillouzo A.

Toxicol Appl Pharmacol. 2010 Nov 15;249(1):91-100. doi: 10.1016/j.taap.2010.08.027. Epub 2010 Sep 15.

PMID:
20816883
34.

Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays.

Le Hegarat L, Dumont J, Josse R, Huet S, Lanceleur R, Mourot A, Poul JM, Guguen-Guillouzo C, Guillouzo A, Fessard V.

Mutagenesis. 2010 Nov;25(6):555-60. doi: 10.1093/mutage/geq039. Epub 2010 Jul 30.

PMID:
20675360
35.

General review on in vitro hepatocyte models and their applications.

Guguen-Guillouzo C, Guillouzo A.

Methods Mol Biol. 2010;640:1-40. doi: 10.1007/978-1-60761-688-7_1. Review.

PMID:
20645044
36.

Liverbeads: a practical and relevant in vitro model for gene induction investigations.

Al Khansa I, Blanck O, Guillouzo A, Bars R.

Drug Metab Dispos. 2010 Sep;38(9):1598-604. doi: 10.1124/dmd.110.033753. Epub 2010 Jun 15.

37.

Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells.

Dumont J, Jossé R, Lambert C, Anthérieu S, Le Hegarat L, Aninat C, Robin MA, Guguen-Guillouzo C, Guillouzo A.

Toxicol Appl Pharmacol. 2010 Jun 1;245(2):256-63. doi: 10.1016/j.taap.2010.03.008. Epub 2010 Mar 20.

PMID:
20307560
38.

Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells.

Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2010 Mar;38(3):516-25. doi: 10.1124/dmd.109.030197. Epub 2009 Dec 17.

39.

Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes.

Piton A, Rauch C, Langouet S, Guillouzo A, Morel F.

Toxicol In Vitro. 2010 Mar;24(2):452-9. doi: 10.1016/j.tiv.2009.09.025. Epub 2009 Oct 12.

PMID:
19833192
40.

Stem cell-derived hepatocytes and their use in toxicology.

Guguen-Guillouzo C, Corlu A, Guillouzo A.

Toxicology. 2010 Mar 30;270(1):3-9. doi: 10.1016/j.tox.2009.09.019. Epub 2009 Oct 6. Review.

PMID:
19815049
41.

Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells.

Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A, Morel F.

Eur J Cancer. 2009 Aug;45(12):2219-27. doi: 10.1016/j.ejca.2009.05.017. Epub 2009 Jun 11.

PMID:
19524433
42.

Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.

Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O.

Toxicol In Vitro. 2009 Jun;23(4):748-53. doi: 10.1016/j.tiv.2009.03.008. Epub 2009 Mar 26.

PMID:
19328226
43.

Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions.

Lambert CB, Spire C, Renaud MP, Claude N, Guillouzo A.

Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.

PMID:
19159669
44.

[In silico, in vitro, in omic experimental models and drug safety evaluation].

Claude N, Goldfain-Blanc F, Guillouzo A.

Med Sci (Paris). 2009 Jan;25(1):105-10. doi: 10.1051/medsci/2009251105. Review. French.

45.

Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells.

Lambert CB, Spire C, Claude N, Guillouzo A.

Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60. doi: 10.1016/j.taap.2008.11.008. Epub 2008 Nov 21.

PMID:
19084549
46.

[New perspectives in the use of human hepatocytes in the preclinical drug development process].

Guillouzo A.

Ann Pharm Fr. 2008 Nov-Dec;66(5-6):288-95. doi: 10.1016/j.pharma.2008.09.002. Epub 2008 Oct 31. Review. French.

PMID:
19061728
47.

Evolving concepts in liver tissue modeling and implications for in vitro toxicology.

Guillouzo A, Guguen-Guillouzo C.

Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1279-94. doi: 10.1517/17425255.4.10.1279 . Review.

PMID:
18798698
48.

Catecholamines induce an inflammatory response in human hepatocytes.

Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A.

Crit Care Med. 2008 Mar;36(3):848-54. doi: 10.1097/CCM.0B013E31816532BE.

PMID:
18431272
49.

Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies.

Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2008 Jun;36(6):1111-8. doi: 10.1124/dmd.107.019901. Epub 2008 Mar 17.

50.

Transcripts of ceruloplasmin but not hepcidin, both major iron metabolism genes, exhibit a decreasing pattern along the portocentral axis of mouse liver.

Troadec MB, Fautrel A, Drénou B, Leroyer P, Camberlein E, Turlin B, Guillouzo A, Brissot P, Loréal O.

Biochim Biophys Acta. 2008 Apr;1782(4):239-49. doi: 10.1016/j.bbadis.2007.12.009. Epub 2008 Jan 3.

Supplemental Content

Loading ...
Support Center